458 related articles for article (PubMed ID: 24495407)
21. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
Holland EA; Schmid H; Kefford RF; Mann GJ
Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
[TBL] [Abstract][Full Text] [Related]
22. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
23. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
Leontieva OV; Blagosklonny MV
Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
[TBL] [Abstract][Full Text] [Related]
24. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.
Eilers G; Czaplinski JT; Mayeda M; Bahri N; Tao D; Zhu M; Hornick JL; Lindeman NI; Sicinska E; Wagner AJ; Fletcher JA; Mariño-Enriquez A
Mol Cancer Ther; 2015 Jun; 14(6):1346-53. PubMed ID: 25852058
[TBL] [Abstract][Full Text] [Related]
25. A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.
Jones R; Ruas M; Gregory F; Moulin S; Delia D; Manoukian S; Rowe J; Brookes S; Peters G
Cancer Res; 2007 Oct; 67(19):9134-41. PubMed ID: 17909018
[TBL] [Abstract][Full Text] [Related]
26. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
27. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
28. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Walker GJ; Flores JF; Glendening JM; Lin AH; Markl ID; Fountain JW
Genes Chromosomes Cancer; 1998 Jun; 22(2):157-63. PubMed ID: 9598804
[TBL] [Abstract][Full Text] [Related]
29. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
30. Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report.
Tang B; Sheng X; Kong Y; Chi Z; Si L; Cui C; Yan X; Mao L; Lian B; Li S; Wang X; Dai J; Bai X; Zhou L; Guo J
Chin Clin Oncol; 2018 Dec; 7(6):62. PubMed ID: 30180747
[TBL] [Abstract][Full Text] [Related]
31. CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas.
Chen Y; Li Z; Fang Q; Wang H; Li C; Gao H; Zhang Y
Int J Mol Med; 2021 Feb; 47(2):500-510. PubMed ID: 33416096
[TBL] [Abstract][Full Text] [Related]
32. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.
Franco J; Witkiewicz AK; Knudsen ES
Oncotarget; 2014 Aug; 5(15):6512-25. PubMed ID: 25156567
[TBL] [Abstract][Full Text] [Related]
33. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
[TBL] [Abstract][Full Text] [Related]
34. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Konecny GE; Winterhoff B; Kolarova T; Qi J; Manivong K; Dering J; Yang G; Chalukya M; Wang HJ; Anderson L; Kalli KR; Finn RS; Ginther C; Jones S; Velculescu VE; Riehle D; Cliby WA; Randolph S; Koehler M; Hartmann LC; Slamon DJ
Clin Cancer Res; 2011 Mar; 17(6):1591-602. PubMed ID: 21278246
[TBL] [Abstract][Full Text] [Related]
35. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
Sheppard KE; McArthur GA
Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445
[TBL] [Abstract][Full Text] [Related]
36. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.
Daniotti M; Ferrari A; Frigerio S; Casieri P; Miselli F; Zucca E; Collini P; Della Torre G; Manoukian S; Peissel B; Bono A; Santinami M; Parmiani G; Rivoltini L; Pilotti S; Rodolfo M
J Invest Dermatol; 2009 Jul; 129(7):1759-68. PubMed ID: 19158841
[TBL] [Abstract][Full Text] [Related]
38. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
39. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma.
Zhang B; Li D; Jin X; Zhang K
Int J Biochem Cell Biol; 2020 Nov; 128():105859. PubMed ID: 32987196
[TBL] [Abstract][Full Text] [Related]
40. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
Semczuk A; Miturski R; Skomra D; Jakowicki JA
Arch Gynecol Obstet; 2004 Jan; 269(2):104-10. PubMed ID: 14648178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]